sirna

DOPE (DOPE) is a neutral helper lipid for cationic liposomes.It is used in combination with cationic phospholipids to increase efficiency during DNA transfection studies as a non-viral method of gene delivery.

SiRNA Negative Control is an siRNA sequence that does not target any gene product and is a negative control for siRNA.

Adenosine Kinase siRNA-2 is a small interfering RNA that targets adenosine kinase messenger RNA (mRNA).

D-Lin-MC3-DMA, an ionizable cationic lipid, serves as a potent siRNA delivery vehicle.

UNC10217938A HCl (UNC7938 HCl) is a 3-deazapteridine analog. UNC10217938A HCl exhibits strong oligonucleotide enhancing effects. UNC10217938A HCl can modulate their intracellular trafficking and release from endosomes, leading to enhance oligonucleotides effects. UNC10217938A HCl also enhances the effects of siRNA and antisense oligonucleotides.

DLinDAP (D-LinDAP) is an ionizable cationic lipid used for SiRNA delivery.

Enoxacin (NSC-629661) is a broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

Enoxacin hydrate (AT-2266 hydrate) is a broad-spectrum 6-fluoronaphthyridinone antibacterial agent.

DODAP is an ionic cationic lipid with low cytotoxicity and high transfection efficiency that can be used to synthesize liposomes and encapsulate biologically active molecules such as mRNA, siRNA and plasmid DNA.

C14-SPM, a branched-chain polyamine lipidoid, facilitates the delivery of siRNA [1].

Inclisiran (unconjugated naked) is a double-stranded small interfering RNA (siRNA) that lacks GalNAc conjugation. This compound selectively inhibits the transcription of PCSK-9, making it applicable in the research of hyperlipidemia and cardiovascular disease (CVD) [1].

Cemdisiran, an investigational N-acetylgalactosamine-conjugated RNAi (RNA interference) agent with terminal sugar modification, is a small interfering RNA (siRNA) designed to specifically target and suppress the C5 mRNA, thereby reducing the liver's production of the complement component C5 [1].

Xalnesiran (sodium) is an siRNA designed for the treatment of chronic hepatitis B (HBV).

Inclisiran (ALN-PCSsc), a double-stranded small interfering RNA (siRNA) compound, serves as the antisense of itself and targets PCSK-9 transcription inhibition. It is employed in the study of hyperlipidemia and cardiovascular disease (CVD) [1].

CLinDMA, a cationic lipid, is known to induce an inflammatory response and serves as a precursor in the synthesis of LNP201, a liposome assembly designed for the systemic delivery of siRNA [1].

NT1-O14B is a novel class of neurotransmitter tryptophan lipids (NT-lipidoids).NT1-O14B can be combined with small molecule drugs (e.g., AmB) and biomolecules (e.g., Tau-ASO) and gene editing proteins (GFP-Cre) to form new neurotransmitter-derived lipid nanoparticles (NT-LNPs) that have blood-brain-barrier (BBB) permeability. Enhanced lipid hydrophobicity and membrane fusion capabilities are commonly used for delivery of nucleic acids such as mRNA, siRNA and DNA.

Mono-Pal-MTO, a palm oil-derived lipid formed by integrating the anticancer agent mitoxantrone (MTO) with palmitoleic acid, exhibits enhanced anticancer activity and efficient siRNA cell delivery when its nanoparticles are mixed with those of di-Pal-MTO at a molar ratio of 1:1 [1].

YSK 05, a pH-sensitive cationic lipid, enhances the intracellular trafficking of non-viral vectors, significantly improves gene silencing and hemolytic activities in its modified form YSK 05-MEND, and effectively overcomes the suppression of endosomal escape caused by PEGylation, thereby enhancing siRNA delivery both in vitro and in vivo [1].

DMG-PEG 2000 (DMG-PEG2000) is a lipid excipient that has been used in combination with other lipids in the formation of lipid nanoparticles. Formulations containing DMG-PEG 2000 have been used in the development of lipid nanoparticles for the delivery of mRNA-based vaccines.

SST-02 is a potent cationic lipid for siRNA-Lipid Nanoparticles. SST-02 possesses a simple chemical structure and is synthesized just in one step. SST-02 showed an ID50 of 0.02 mg/kg in the factor VII (FVII) model. Rats administered with 3 mg/kg of SST-02

(Rac)-Z-Phe-Phe-FMK (Cathepsin L-IN-2) is a cathepsin L inhibitor that inhibits the tendency of β-amyloid to induce apoptotic changes .

VnP-16, a synthetic peptide fragment mirroring amino acids 270-281 of vitronectin (a multifunctional glycoprotein involved in cell attachment, migration, and spreading), promotes attachment and spreading of isolated human osteogenic cells. This effect is reversible with β1 integrin siRNA knockdown when VnP-16 is applied at 9.1 µg/cm2 on cell plates. The compound enhances osteogenesis in human skin-derived mesenchymal precursors and MC3T3-E1 mouse calvarial osteoblast precursors. Furthermore, in vivo studies show VnP-16 mitigates IL-1α-induced bone loss, reduces calvarial osteoclast numbers in mice, increases bone mineral density, and lessens trabecular bone loss in a mouse model of ovariectomy-induced bone loss.

CL4H6, a pH-sensitive cationic lipid, serves as the primary constituent of lipid nanoparticles (LNPs). These LNPs are instrumental in targeting and delivering siRNA, leading to a potent gene-silencing response [1] [2].

DSPE-PEG(2000) maleimide is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE). This compound is frequently utilized both in vitro and in vivo for synthesizing lipid nanoparticles (LNPs) that deliver siRNA or small molecule anticancer drugs. In experiments, LNPs containing DSPE-PEG(2000) maleimide and encapsulating siRNA targeting the mRNAs for p53 and K-RAS induced tumor regression in a PANC-1 pancreatic ductal adenocarcinoma mouse xenograft model.